Tower Research Capital (TRC)’s Protara Therapeutics TARA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24K | Buy |
4,603
+2,530
| +122% | +$15K | ﹤0.01% | 3348 |
|
|
2025
Q4 | $11K | Sell |
2,073
-3,514
| -63% | -$19.5K | ﹤0.01% | 3659 |
|
|
2025
Q3 | $24.3K | Buy |
5,587
+1,153
| +26% | +$3.73K | ﹤0.01% | 3126 |
|
|
2025
Q2 | $13.4K | Buy |
4,434
+4,287
| +2,916% | +$14.8K | ﹤0.01% | 3862 |
|
|
2025
Q1 | $626 | Buy |
147
+30
| +26% | +$134 | ﹤0.01% | 4853 |
|
|
2024
Q4 | $618 | Sell |
117
-2,666
| -96% | -$8.61K | ﹤0.01% | 5221 |
|
|
2024
Q3 | $5.09K | Sell |
2,783
-1,236
| -31% | -$2.54K | ﹤0.01% | 4332 |
|
|
2024
Q2 | $8.36K | Buy |
4,019
+1,439
| +56% | +$4.21K | ﹤0.01% | 4361 |
|
|
2024
Q1 | $10.3K | Sell |
2,580
-1,758
| -41% | -$5.67K | ﹤0.01% | 3708 |
|
|
2023
Q4 | $8.13K | Sell |
4,338
-456
| -10% | -$672 | ﹤0.01% | 4538 |
|
|
2023
Q3 | $8.01K | Buy |
4,794
+2,583
| +117% | +$5.92K | ﹤0.01% | 4409 |
|
|
2023
Q2 | $5.28K | Buy |
+2,211
| New | +$6.57K | ﹤0.01% | 4843 |
|
|
2023
Q1 | – | Sell |
-133
| Closed | – | – | 6265 |
|
|
2022
Q4 | $0 | Buy |
+133
| New | +$420 | ﹤0.01% | 6366 |
|
|
2022
Q3 | – | Sell |
-1,807
| Closed | -$5K | – | 6478 |
|
|
2022
Q2 | $5K | Buy |
+1,807
| New | +$6.61K | ﹤0.01% | 5101 |
|
|
2022
Q1 | – | Sell |
-799
| Closed | -$6K | – | 6545 |
|
|
2021
Q4 | $6K | Buy |
+799
| New | +$5.51K | ﹤0.01% | 5067 |
|
|
2021
Q3 | – | Sell |
-1,548
| Closed | -$15K | – | 6161 |
|
|
2021
Q2 | $15K | Sell |
1,548
-180
| -10% | -$2.04K | ﹤0.01% | 4144 |
|
|
2021
Q1 | $27K | Buy |
1,728
+606
| +54% | +$11.2K | ﹤0.01% | 3650 |
|
|
2020
Q4 | $27K | Sell |
1,122
-706
| -39% | -$15.2K | ﹤0.01% | 3666 |
|
|
2020
Q3 | $31K | Buy |
1,828
+1,736
| +1,887% | +$40.3K | ﹤0.01% | 3717 |
|
|
2020
Q2 | $3K | Buy |
92
+53
| +136% | +$1.64K | ﹤0.01% | 4429 |
|
|
2020
Q1 | $1K | Buy |
+39
| New | +$1.14K | ﹤0.01% | 2848 |
|
|
2017
Q3 | – | Sell |
-67
| Closed | -$4K | – | 4131 |
|
|
2017
Q2 | $4K | Sell |
67
-100
| -60% | -$5.6K | ﹤0.01% | 2123 |
|
|
2017
Q1 | $12K | Buy |
167
+130
| +351% | +$9.71K | ﹤0.01% | 1651 |
|
|
2016
Q4 | $3K | Sell |
37
-10
| -21% | -$3.16K | ﹤0.01% | 3292 |
|
|
2016
Q3 | $18K | Sell |
47
-11
| -19% | -$3.87K | ﹤0.01% | 1689 |
|
|
2016
Q2 | $18K | Buy |
58
+25
| +76% | +$7.48K | ﹤0.01% | 2335 |
|
|
2016
Q1 | $10K | Sell |
33
-65
| -66% | -$20.9K | ﹤0.01% | 1982 |
|
|
2015
Q4 | $61K | Buy |
+98
| New | +$57.5K | 0.01% | 466 |
|
|
2015
Q3 | – | Sell |
-21
| Closed | -$15K | – | 4738 |
|
|
2015
Q2 | $15K | Buy |
21
+16
| +320% | +$9.9K | ﹤0.01% | 2360 |
|
|
2015
Q1 | $2K | Buy |
5
+2
| +67% | +$878 | ﹤0.01% | 3824 |
|
|
2014
Q4 | $1K | Buy |
+3
| New | +$1.21K | ﹤0.01% | 3722 |
|
Other funds holding TARA
VCIM
VCM
SCM
ACA
IHAM
ACM
Tower Research Capital (TRC)'s TARA Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Protara Therapeutics (TARA) stake by 122% in Q1 2026, buying an estimated $15K and bringing the position to 4,603 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #3348.
Tower Research Capital (TRC) first reported a position in TARA in Q4 2014 and has held it in 31 quarters since. The position peaked at $61K in Q4 2015. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.
- Tower Research Capital (TRC) held 4,603 shares of Protara Therapeutics worth $24K as of Q1 2026.
- Tower Research Capital (TRC) bought 2,530 Protara Therapeutics shares in Q1 2026, an estimated $15K.
- Protara Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3348 holding.
- Tower Research Capital (TRC) first reported a position in Protara Therapeutics in Q4 2014 and has held it in 31 quarters since.
- Tower Research Capital (TRC)'s Protara Therapeutics position peaked at $61K in Q4 2015.
- 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.